During the corresponding time, Sarepta Therapeutics Inc saw a revenue deteriorated by -34.34 % year on year, sequentially revenue fell by -45.09 %. While revenue at the Sarepta Therapeutics Inc 's corporate clients
Sarepta Therapeutics Inc's Comment on Sales, Marketing and Customers
Sarepta holds licensing agreements with the BioMarin Parties and the University of Western Australia (UWA) concerning patent rights and compounds for treating Duchenne muscular dystrophy. The products EXONDYS 51, VYONDYS 53, and AMONDYS 45 are covered under the UWA License Agreement. Under these arrangements, the BioMarin Parties receive milestone payments and royalties based on net sales of products covered by the Licensed Patents, with payments segmented by geographic markets. Sarepta is obligated to make milestone payments to UWA and pay royalties on net sales of products covered by UWA patents. Additionally, Sarepta has a supply agreement with Catalent Maryland, Inc.; however, specific details of this agreement are not provided.
CAMBRIDGE, Mass. Sarepta Therapeutics, Inc. (NASDAQ: SRPT), renowned for its pioneering work in precision genetic medicine for rare diseases, recently announced that the rAAVrh74 viral vector utilized in its investigational gene therapy SRP-9003 (bidridistrogene xeboparvovec) has received a platform technology designation from the U.S. Food and Drug Administration (FDA). This designation marks a significant milestone, positioning Sarepta at the forefront of gene therapy innovation, particularly for patients suffering from Limb Girdle Muscular Dystrophy Type 2E/R4, one of the many debilitating conditions impacting muscular function.The FDA s recognition of the rAAVrh74 vector underscores its potential appli...
: Sarepta Therapeutics, a trailblazer in the realm of precision genetic medicine, made a significant stride in fortifying its workforce and commitment to therapeutic innovations by granting equity awards under Nasdaq Listing Rule 5635(c)(4). These awards, as announced on October 31, 2024, were strategically allocated to 15 new hires under Sarepta’s 2024 Employment Commencement Incentive Plan. This article delves into the implications of such equity grants on the biotechnology industry, particularly focusing on recruiting and retaining top talent in the competitive field of rare disease therapeutics, and examines the broader context of employing equity inducements within the Nasdaq framework.Biotechnology c...
Sarepta Therapeutics, a leading precision genetic medicine company focused on rare diseases, has officially opened the annual Route 79 Duchenne Scholarship Program for the 2024-2025 academic year. This program aims to support and empower individuals living with Duchenne muscular dystrophy (DMD) and their siblings by awarding academic scholarships of up to $5,000. The application deadline is Monday, May 13, 2024, at 11:59 pm.Understanding Duchenne Muscular Dystrophy (DMD)DMD is a rare genetic disorder characterized by progressive muscle weakness and deterioration. It primarily affects boys, with symptoms usually appearing in early childhood. DMD is caused by a mutation in the dystrophin gene, resulting in the...
Sarepta Therapeutics Inc’s Comment on Sales, Marketing and Customers
Sarepta holds licensing agreements with the BioMarin Parties and the University of Western Australia (UWA) concerning patent rights and compounds for treating Duchenne muscular dystrophy. The products EXONDYS 51, VYONDYS 53, and AMONDYS 45 are covered under the UWA License Agreement. Under these arrangements, the BioMarin Parties receive milestone payments and royalties based on net sales of products covered by the Licensed Patents, with payments segmented by geographic markets. Sarepta is obligated to make milestone payments to UWA and pay royalties on net sales of products covered by UWA patents. Additionally, Sarepta has a supply agreement with Catalent Maryland, Inc.; however, specific details of this agreement are not provided.
Sources:
Sarepta Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Sarepta Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Sarepta Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
49.87 %